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Summary
Tissue factor (TF) is a member of the cytokine receptor superfamily and binds FVII/VIIa. The
TF:FVIIa complex has both procoagulant and signaling activities. It functions in many biological
processes, including hemostasis, thrombosis, inflammation, angiogenesis and tumor growth.
Importantly, TF is essential for hemostasis. However, increased TF expression within atherosclerotic
plaques and elevated levels of circulating TF-positive micro particles promote thrombosis. TF
increases inflammation by enhancing intravascular fibrin deposition, by increasing the formation of
pro-inflammatory fragments of fibrin and by generating coagulation proteases, including FVIIa, FXa
and thrombin, that activate protease-activated receptors (PARs). In endotoxemia and sepsis, TF-
dependent thrombin generation and activation of PAR1 on dendritic cells enhance inflammation.
Finally, the TF:FVIIa complex contributes to tumor growth by activating PAR2.
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Introduction
TF plays a role in many biological processes. However, a major challenge to studying TF in
these processes is that knock-out of the TF gene in mice is lethal and inhibition of TF can
induce hemorrhage. However, these problems have been overcome with the development of
pharmacologic tools and genetic approaches. For instance, a monoclonal antibody called
10H10 was identified that inhibits TF-dependent signaling without affecting TF procoagulant
activity. This antibody can be used to study TF signaling without affecting hemostasis. To
circumvent the problem of embryonic lethality, we made mice (‘low-TF’ mice) that express
low levels of TF in all tissues (1% of wild-type levels). In addition, we made mice that have
the TF gene deleted in a cell type-specific manner, including in myeloid cells (TFflox/flox,
LysMCre) and in vascular smooth muscle cells (TFflox/flox, SM22Cre). Because of space
limitations, some primary references could not be included in the review.
Hemostasis
TF is expressed by cells in the blood vessel wall and activates the clotting cascade after vascular
injury (Fig. 1). A recent study showed that vessel wall TF is pre-bound with FVII [1]. TF is
also expressed in a tissue-specific manner [2]. Interestingly, either a genetic deficiency of TF
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expression or inhibition of TF in wild-type mice leads to tissue-specific hemorrhage in tissues
with high levels of expression, such as the brain and heart. This suggests that TF-dependent
thrombin generation is required for hemostasis in vital organs.
The TF:FVIIa complex also participates in ‘idling’ of the clotting cascade. This is defined as
a low basal activation of clotting that occurs in healthy individuals [3]. Hematopoietic cell-
derived TF appears to mediate idling because the basal level of thrombin–antithrombin (TAT)
complex in plasma is decreased in wild-type mice containing bone marrow from low TF mice
[4].
Thrombosis
Pathologic TF expression can trigger arterial thrombosis, venous thrombosis and disseminated
intravascular coagulation (DIC) (Fig. 1). In contrast to the high levels of TF in the vessel wall,
only very low levels of TF are present in blood of healthy individuals. This so-called
‘circulating TF’ consists mainly of TF-positive micro particles (MP), which are submicron
membrane fragments derived from activated and/or apoptotic cells. Unstimulated monocytes
express low levels of TF and may be the primary source of these MPs. Importantly, levels of
TF-positive MP are increased in a variety of diseases, including cardiovascular disease, sepsis
and cancer [5]. These TF-positive MP most likely contribute to thrombosis.
In humans, atherosclerotic plaques contain large amounts of TF and this triggers thrombosis
after plaque rupture. In healthy mice, vessel wall TF mediates the formation of an occlusive
thrombus in a carotid artery injury model [6]. In contrast, both vessel wall-and hematopoietic
cell-derived TF contribute to thrombosis in a laser-induced injury model of mouse cremaster
arterioles [7]. Recently, we used TFflox/flox, SM22Cre mice to show that deletion of the TF
gene in vascular smooth muscle cells in mice reduced carotid arterial thrombosis [8].
Venous thrombosis is triggered by a combination of factors that include increased
thrombogenicity of blood. As venous thrombosis is generally not associated with vessel-wall
damage, it is likely that circulating TF rather than vessel-wall TF triggers venous thrombosis.
One study showed that MPs isolated from pericardial blood of cardiac surgery patients
promoted TF-dependent venous thrombosis in a rat model [9]. However, we found that in
healthy mice hematopoietic cell-derived TF did not contribute to venous thrombosis in an
inferior vena cava ligation model [6].
Cancer patients exhibit a high rate of venous thrombosis. A recent retrospective study found
elevated levels of TF-positive micro-particle activity in plasma from patients with breast and
pancreatic cancer [10]. In a prospective study, we found that pancreatic cancer patients with
elevated levels of TF-positive micro-particle activity developed venous thromboembolism
[11]. These studies suggest that circulating TF may contribute to venous thrombosis in cancer
patients. Moreover, levels of TF-positive micro-particle activity may be a useful biomarker to
identify cancer patients with an increased risk of thrombosis. Other studies have analyzed levels
of circulating TF in mouse tumor models. We found that human colorectal tumors grown in
mice release human TF antigen into the circulation [12]. Another study found a positive
correlation between levels of plasma TAT complex and tumor-derived human TF activity from
mice containing human pancreatic tumors [13]. These results suggest that circulating tumor-
derived TF activates the clotting cascade in mice and may promote venous thrombosis.
Inhibition of the TF:FVIIa complex with a variety of inhibitors reduces DIC in animal models
of endotoxemia and sepsis. In vitro and in vivo studies have shown that lipopolysaccharide
(LPS) released from Gram-negative bacteria is a potent inducer of TF expression in monocytes
[5]. In a human endotoxemia model, monocytes express TF and release TF-positive micro-
particles into the circulation [5]. We found that reducing TF expression in hematopoietic cells
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decreased levels of TAT complex in a murine endotoxemia model [4]. Similarly, we used
TFflox/flox, LysMCre mice to show that deletion of the TF gene in myeloid cells decreases
levels of TAT complex after administration of LPS (Pawlinski and Mackman, unpublished
data). In septic baboons, TF antigen is also observed on the surface of endothelial cells at branch
points of the aorta [14]. However, this TF antigen may be attributable to the deposition of
leukocyte-derived, TF-positive micro-particles on the activated endothelium. In support of this
notion, a recent study showed that TF staining of neutrophils isolated from LPS-stimulated
human whole blood was caused by binding of monocyte-derived, TF-positive micro-particles
[15]. These results indicate that monocytes are the major source of inducible intravascular TF
that leads to DIC in endotoxemia and sepsis.
Inflammation
Many studies have shown that TF contributes to inflammation in a variety of disease models,
including endotoxemia, sepsis and ischemia-reperfusion (I/R) (Fig. 1) [16]. For instance,
inhibition of TF in a baboon model of sepsis reduced circulating levels of the pro-inflammatory
cytokines IL-6 and IL-8, and mortality. In contrast, an active site inhibited FXa molecule
reduced DIC without reducing mortality. We found that low TF mice had reduced levels of
TAT and IL-6 compared with control mice in an endotoxemia model [4]. These studies
suggested that TF-dependent signaling enhances inflammation during endotoxemia. Recently,
it was reported that endotoxemic PAR1−/− mice expressed lower levels of IL-6 and exhibited
reduced mortality compared with wild-type littermate controls [17]. Inhibition of thrombin in
wild-type mice was also protective. Further studies indicated that TF-dependent thrombin
generation and PAR-1 signaling in dendritic cells amplifies both inflammation and coagulation
[16].
TF also enhances inflammation associated with I/R injury. Neutrophils contribute to
reperfusion injury by releasing oxygen radicals and inflammatory mediators. We showed that
inhibition of TF in a rabbit model of cardiac I/R injury reduced the expression of inflammatory
mediators, reduced recruitment of neutrophils and also reduced infarct size [18]. Inhibition of
thrombin provided a similar protection. Thrombin may increase infarct size either by activating
PAR1 and/or by enhancing fibrin deposition. Surprisingly, we found that PAR1 deficiency did
not affect infarct size [19]. In contrast, a deficiency of fibrinogen was associated with a decrease
in infarct size [20]. Further studies demonstrated that the E1 fragment, which is derived from
degradation of fibrin, facilitates the recruitment of neutrophils into the myocardium by binding
to VE-cadherin at endothelial cell junctions and the integrin CD11c/CD18 on neutrophils
[16].
TF may also increase infarct size by activating PAR2. A recent study showed that active site-
inhibited FVIIa reduced inflammation and infarct size in a mouse model of cardiac I/R injury
[21]. We found that PAR2−/− mice had smaller infarcts than wild-type littermates (Pawlinski
and Mackman, unpublished data). However, further studies are required to determine the role
of the TF:FVIIa-PAR2 signaling pathway in cardiac I/R injury.
Importantly, different TF-dependent pathways appear to enhance inflammation in different
models (Fig. 1) [16]. For instance, we found that PAR1−/− mice, but not PAR2−/− mice, have
reduced inflammation in a kidney I/R model, suggesting that a TF-thrombin-PAR1 pathway
drives inflammation in this model [22]. In another study, inhibition of TF reduced inflammation
in a model of colitis [23]. In antiphospholipid syndrome (APS), complement C5a induces TF
expression on neutrophils [24]. In collaboration with Dr Girardi, we found that injection of an
antiphospholipid antibody into pregnant mice induced TF expression on neutrophils and
PAR2-dependent generation of reactive oxygen species and fetal loss [25]. Further studies are
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needed to identify the cell types that express TF in different pathologic settings and how TF-
dependent pathways enhance inflammation.
Tumor growth and metastasis
TF is expressed by tumor cells and plays a role in metastasis by activating the clotting cascade.
Early studies indicated that it also enhanced tumor growth and angiogenesis. However, these
studies were largely descriptive and it was not until recently that a direct role for TF in tumor
growth was shown. In collaboration with Dr Rak, we found that knock-down of TF expression
with short interfering RNA (siRNA) in colorectal cancer cells dramatically reduced tumor
growth in mice but did not affect tumor growth in vitro [12]. Other studies have shown that
pharmacologic inhibition of the TF:FVIIa complex reduces tumor growth in mice [26–28].
The most likely explanation for these results is that TF on the surface of tumor cells binds
plasma FVIIa and that this cleaves PAR2. In support of this notion, selective inhibition of
TF:FVIIa signaling using 10H10 reduced breast tumor growth in mice [29]. Finally, in a mouse
model of spontaneous mammary tumors a deficiency of PAR2, but not PAR1, reduced tumor
growth [30]. The precise mechanism by which the TF:FVIIa-PAR2 pathway increases tumor
growth is not known but possibilities include enhancing tumor survival and/or increasing
angiogenesis. TF-dependent thrombin generation and activation of PAR1 on tumor cells may
also increase the growth of some tumors.
Conclusion
This review shows that TF plays a critical role in a diverse set of biological processes. However,
further studies are required to address several unresolved issues: (i) Does circulating TF
contribute to the propagation of a hemostatic clot in healthy individuals? (ii) Do TF-positive
micro-particles induce venous thrombosis and can it be used as a biomarker of thrombotic risk?
(iii) What is the role of platelet TF? and (iv) What is the relative importance of
phosphatidlyserine exposure vs. oxidation of the Cys186/Cys208 pair in the regulation of TF
activity in different cell types?
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TF-dependent procoagulant and signaling pathways. TF plays an essential role in coagulation
by generating coagulation proteases and inducing fibrin deposition. Non-coagulant roles of TF
in other biological processes include the formation of fibrin degradation products (FDP) and
the generating coagulation proteases that activate PAR1 and PAR2. Thrombin also activates
PAR3 and PAR4 (not shown).
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